Results 21 to 30 of about 178,517 (322)

Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.

New England Journal of Medicine, 2022
BACKGROUND Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL).
E. Wang, Xiaoli Mi, Meghan C. Thompson, S. Montoya, R. Notti, Jumana Afaghani, B. Durham, A. Penson, Matthew T. Witkowski, Sydney X Lu, J. Bourcier, Simon J. Hogg, C. Erickson, Daniel Cui, Hana Cho, Michael Singer, T. Totiger, S. Chaudhry, M. Geyer, Alvaro J Alencar, A. Linley, M. Palomba, Catherine C Coombs, Jae H. Park, A. Zelenetz, L. Roeker, M. Rosendahl, D. E. Tsai, K. Ebata, B. Brandhuber, D. Hyman, I. Aifantis, A. Mato, Justin Taylor, O. Abdel-Wahab   +34 more
semanticscholar   +1 more source

Novel Bruton's tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis.

PLoS ONE, 2023
Rheumatoid arthritis is an inflammatory autoimmune disease, characterized by autoantibody production, synovial inflammation, and joint destruction. Its pathogenesis is due to environmental factors and genetic backgrounds.
Daichi Akasaka, Satoru Iguchi, Ryusuke Kaneko, Yohei Yoshiga, Daisuke Kajiwara, Yoshinori Nakachi, Naruto Noma, Kenji Tanaka, Atsushi Shimizu, Fumihito Hosoi   +9 more
doaj   +1 more source

Disseminated fungal infection in a patient receiving zanubrutinib

Clinical Case Reports, 2023
Key Clinical Message We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.
Madalyn Walsh, Alice Xu, Zuhair Ballas, Rolando Sanchez   +3 more
doaj   +1 more source

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Molecules, 2023
In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and ...
D. Rozkiewicz, J. Hermanowicz, Iwona Kwiatkowska, A. Krupa, D. Pawlak   +4 more
semanticscholar   +1 more source

The role of Bruton's tyrosine kinase in the immune system and disease

Immunology, 2021
Bruton's tyrosine kinase (BTK) is a TEC kinase with a multifaceted role in B‐cell biology and function, highlighted by its position as a critical component of the B‐cell receptor signalling pathway.
Charlotte McDonald, Charalambos Xanthopoulos, E. Kostareli   +2 more
semanticscholar   +1 more source

Second-generation inhibitors of Bruton tyrosine kinase [PDF]

Journal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported.
Jingjing Wu, Christina Liu, Delong Liu, Stella T. Tsui   +3 more
openaire   +3 more sources

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

eJHaem, 2021
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi, Mohammad‐Ali Okhovat, Layung Sekar Sih Wikanthi, Ann Svensson, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat‐Farsangi   +9 more
doaj   +1 more source

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma

Neuro-Oncology, 2020
Background The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton’s tyrosine kinase inhibitor, were evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL ...
Y. Narita, M. Nagane, K. Mishima, Y. Terui, Y. Arakawa, Hajime Yonezawa, K. Asai, N. Fukuhara, K. Sugiyama, N. Shinojima, Junsaku Kitagawa, Arata Aoi, R. Nishikawa   +12 more
semanticscholar   +1 more source

Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib

Journal of Neurological Surgery Reports, 2022
Spontaneous spinal subdural hematomas (SSH) are rare occurrences that can occur most commonly secondary to vascular malformations or coagulopathies. Only a small fraction of spontaneous SSHs are caused by acquired coagulation disorders such as leukemia ...
John Lynes, Sebastian Rubino, Andrea Rogers, Sameh Gaballa, Hien D. Liu, John A. Arrington, Edwin Peguero, James K. C. Liu   +7 more
doaj   +3 more sources

A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase

Royal Society Open Science, 2021
Bruton's tyrosine kinase (BTK) plays a vital role in mature B-cell proliferation, development and function. Its inhibitors have gradually been applied for the treatment of many B-cell malignancies. However, because of treatment-associated drug resistance
Simei Qiu, Yunfeng Liu, Quhuan Li
doaj   +1 more source